Hepatocellular Carcinoma Patient Liver Function and Treatment Response Data

151 patients with unresectable hepatocellular carcinoma were retrospectively enrolled to study liver function changes during atezolizumab plus bevacizumab therapy. The dataset includes albumin–bilirubin (ALBI) scores at baseline and 6 weeks post-treatment, correlated with initial therapeutic response and overall survival. This supplementary material was authored by figshare admin karger and last updated in May 2026.

Use Cases

• Analyzing the relationship between initial therapeutic response and changes in liver function based on ALBI score dynamics.
• Evaluating the prognostic value of 6-week ALBI score for overall survival prediction in HCC patients.
• Comparing liver function outcomes between patient groups achieving complete/partial response versus stable/progressive disease.

Strengths

• Includes data from 151 patients with unresectable hepatocellular carcinoma.
• Provides specific statistical results, such as a 46% vs. 25% improvement rate in ALBI score between response groups (P=0.018).
• Identifies a prognostic cut-off value (-1.95) for the 6-week ALBI score with an AUC of 0.763 for 12-month survival.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• Data is a 124.1 KB DOCX file, indicating a very small and likely summary-level dataset.
• The retrospective study design may reflect inherent selection biases from the participating multicenter institutions.

Provenance

Source

figshare

Collection Method

Retrospective multicenter analysis of patient records.

Freshness

Last updated 2026-05-09 07:55:15